Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 235

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 235
---
 of 6% per annum and a conversion price of $2.42 per
share. The Sep 23 Note is secured by a first priority lien and security interest on certain shares that we own (“Collateral”).
Upon our disposal of all or a portion of the Collateral, the investor has the right, to request that we prepay the then-remaining outstanding
balance of the Sep 23 Note, in part or in full and we can make that payment in cash or in shares.

On March 1, 2024, we entered into an Agreement and Plan of Merger with
YOOV Group Holding Limited, a company organized under the laws of British Virgin Islands (“YOOV”), pursuant to which YOOV
was to become one of our wholly owned subsidiaries. However, on October 25, 2024, the parties to the Agreement and Plan of Merger entered
into a termination agreement (the “Termination Agreement”), pursuant to which the parties agreed to terminate the Agreement
and Plan of Merger on the date thereof, and such agreement became null and void and of no further force or effect.

<div align='center'>120</div>

On April 8, 2024, CGY Investments
Limited and DSF Investment Holdings Limited voluntarily converted 401,537 Class B Ordinary Shares and 45,305 Class B Ordinary Shares,
respectively into Class A Ordinary Shares on a one-for-one basis. Upon conversion, 1,796,934 Class B Ordinary Shares were issued and outstanding,
CGY Investments Limited owned 533,575 Class A Ordinary Shares and did not own any Class B Ordinary Share; and DSF Investment Holdings
Limited owned 45,305 Class A Ordinary Shares and did not own any Class B Ordinary Share.

On January 2, 2025, the Company
entered into a certain securities purchase agreement with certain non-affiliated institutional investors pursuant to which the Company
sold 1,535,000 Class A Ordinary Shares of the Company, par value $0.00001 per share at a per share price of $2.00 in a registered direct
offering, for gross proceeds of $3,070,000.

Over the past three years,
we have invested approximately $0.2 million towards our principal capital expenditures, which include laboratory equipment, leasehold
improvements, and other equipment.

The following diagram illustrates
our corporate structure as of the date of this prospectus:

Note 1: Dr. Clark Cheng, a previous Executive